Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (0K6R.L) Financial Performance & Income Statement Overview
Analyze Neurocrine Biosciences, Inc. (0K6R.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Neurocrine Biosciences, Inc. (0K6R.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Neurocrine Biosciences, Inc. 0K6R.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $572.60M | $627.70M | $622.10M | $590.20M |
| Cost of Revenue | $9.20M | $9.30M | $8.00M | $15.60M |
| Gross Profit | $563.40M | $618.40M | $614.10M | $574.60M |
| Gross Profit Ratio | $0.98 | $0.99 | $0.99 | $0.97 |
| R&D Expenses | $263.20M | $185.60M | $195.00M | $184.70M |
| SG&A Expenses | $276.50M | $287.80M | $234.30M | $242.00M |
| Operating Expenses | $539.80M | $476.40M | $430.30M | $426.70M |
| Total Costs & Expenses | $549.00M | $494.20M | $438.30M | $442.30M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $49.70M |
| Depreciation & Amortization | $0.00 | $7.10M | $6.50M | $7.30M |
| EBITDA | $23.60M | $169.70M | $191.30M | $155.20M |
| EBITDA Ratio | $0.04 | $0.27 | $0.31 | $0.26 |
| Operating Income | $23.60M | $142.00M | $183.80M | $147.90M |
| Operating Income Ratio | $0.04 | $0.23 | $0.30 | $0.25 |
| Other Income/Expenses (Net) | -$8.90M | $20.60M | $6.50M | -$46.80M |
| Income Before Tax | $14.70M | $162.60M | $190.30M | $98.60M |
| Income Before Tax Ratio | $0.03 | $0.26 | $0.31 | $0.17 |
| Income Tax Expense | $6.80M | $59.50M | $60.50M | $33.60M |
| Net Income | $7.90M | $103.10M | $129.80M | $65.00M |
| Net Income Ratio | $0.01 | $0.16 | $0.21 | $0.11 |
| EPS | $0.08 | $1.03 | $1.28 | $0.64 |
| Diluted EPS | $0.08 | $1.00 | $1.24 | $0.63 |
| Weighted Avg Shares Outstanding | $99.70M | $100.00M | $101.10M | $100.80M |
| Weighted Avg Shares Outstanding (Diluted) | $102.50M | $102.90M | $104.30M | $103.90M |
Over the last four quarters, Neurocrine Biosciences, Inc. achieved steady financial progress, growing revenue from $590.20M in Q2 2024 to $572.60M in Q1 2025. Gross profit stayed firm with margins at 98% in Q1 2025 versus 97% in Q2 2024. Operating income totaled $23.60M in Q1 2025, maintaining a 4% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $23.60M. Net income dropped to $7.90M, with EPS at $0.08. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan